問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Cardiovascular Diseases

更新時間：2023-09-19

張伯丞
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

6Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

張伯丞

List

12Cases

2026-03-01 - 2030-10-09

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Not yet recruiting9Sites

Recruiting4Sites

2026-01-02 - 2029-09-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2024-07-30 - 2028-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting8Sites

Recruiting4Sites

2026-01-01 - 2031-09-18

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

2024-02-27 - 2030-01-27

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

Suspended15Sites

2025-09-30 - 2032-03-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2026-02-01 - 2029-02-28

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-05-08 - 2027-07-02

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

2016-11-01 - 2021-04-10

Phase III

A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction

  • Condition/Disease

    acute myocardial infarction

  • Test Drug

    LCZ696

Participate Sites
9Sites

Not yet recruiting2Sites

Terminated7Sites

2009-05-01 - 2015-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB